**Supplementary Information**

The protein concentration of the lots of PF-06438179/GP1111, infliximab‑EU, and infliximab‑US used in the PK study are provided in Supplementary Table 1.

**Supplementary Table 1.** Protein concentration of test and reference products

|  |  |
| --- | --- |
| Product | Protein concentration (mg/mL) |
| PF-06438179/GP1111 | 10.3 |
| Infliximab‑EU | 9.5 |
| Infliximab‑US | 9.7 |

EU, European Union; US, United States

The following formula was used to calculate the protein-content corrected value for each subject’s PK exposure parameters (**Supplementary Figure 1**).

**Supplementary Figure 1.** Calculation of protein-content corrected PK parameters



Statistical comparisons of the protein-content corrected PK exposure parameters between the test (PF-06438179/GP1111), and reference products (infliximab‑EU, and infliximab‑US) are shown in **Supplementary Table 2**.

**Supplementary Table 2.** Statistical comparison of protein-content corrected PK exposure parameters between test and reference products: Per-protocol analysis set

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | **Adjusted geometric mean** |
| **Test** | **Reference** | **Parameter** | **Test** | **Reference** | **Ratio (%)a** | **90% CI (%)** |
| PF-06438179/GP1111 | Infliximab-EU | Cmax, μg/mL | 211.1 | 208.0 | 101.48 | 93.45 – 110.21 |
|  | AUCT, μg·h/mL | 53990 | 52270 | 103.29 | 94.86 – 112.45 |
|  | AUCinf, μg·h/mL | 58010 | 56930 | 101.91 | 92.85 – 111.86 |
| PF-06438179/GP1111 | Infliximab-US | Cmax, μg/mL | 211.1 | 209.4 | 100.81 | 92.79 – 109.53 |
|  | AUCT, μg·h/mL | 53990 | 53240 | 101.40 | 93.09 – 110.45 |
|  | AUCinf, μg·h/mL | 58010 | 57540 | 100.83 | 91.81 – 110.73 |
| Infliximab-EU | Infliximab-US | Cmax, μg/mL | 208.0 | 209.4 | 99.34 | 91.61 – 107.72 |
|  |  | AUCT, μg·h/mL | 52270 | 53240 | 98.17 | 90.31 – 106.73 |
|  |  | AUCinf, μg·h/mL | 56930 | 57540 | 98.94 | 90.29 – 108.41 |

aTest/reference ratio of adjusted geometric means.

AUCinf, area under the concentration–time curve from time 0 extrapolated to infinite time; AUCT, area under the concentration–time curve from time 0 to last time point of measurable concentration; CI, confidence interval; Cmax, maximum serum concentration; PK, pharmacokinetic